Press Releases

Date Title
Toggle Summary Kura Oncology Added to Nasdaq Biotechnology Index
SAN DIEGO , Dec. 18, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that it has been selected for addition to the Nasdaq Biotechnology Index (Nasdaq:NBI),
Toggle Summary Kura Oncology Identifies Potential Biomarkers of Activity for Lead Candidate Tipifarnib in Bone Marrow Cancers
CXCR4/CXCR2 expression ratio and bone marrow homing of myeloid cells identified as potential markers for tipifarnib in MDS, AML and CMML CXCL12/CXCR4 pathway a potential therapeutic target of farnesyl transferase inhibitors Findings support development of tipifarnib in certain bone marrow cancers
Toggle Summary Kura Oncology Reports Positive Phase 2 Study of Tipifarnib in Chronic Myelomonocytic Leukemia
– Primary objective met with three objective responses in nine patients with RAS wild-type tumor status (33%), two additional RAS wild-type patients pending best response evaluation – – All nine evaluable patients with RAS wild-type achieved stable disease or better – – Preliminary data presented
Toggle Summary Kura Oncology to Host Investor Day on November 16, 2017
SAN DIEGO , Nov. 09, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. , (Nasdaq:KURA) a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that it will host an Investor Day on Thursday, November 16, 2017 , from 8:30 a.m.
Toggle Summary Kura Oncology Reports Third Quarter 2017 Financial Results and Provides Corporate Update
Management to host webcast and conference call today at 4:30 p.m. ET SAN DIEGO , Nov. 07, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. , (Nasdaq:KURA) a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today reported third quarter 2017
Toggle Summary Kura Oncology Announces Upcoming Presentations at American Society of Hematology Annual Meeting
SAN DIEGO , Nov. 01, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that four abstracts relating to the Company’s lead product candidate, tipifarnib, have been
Toggle Summary Kura Oncology to Report Third Quarter 2017 Financial Results
SAN DIEGO , Oct. 31, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that it will report third quarter 2017 financial results after the close of U.S.
Toggle Summary Kura Oncology Development Candidate KO-539 Shows Robust Preclinical Anti-Tumor Activity in NPM1- and DNMT3A-Mutant AML
NPM1 and DNMT3A-mutants comprise approximately 45% of AML patients Menin-MLL complex appears to be central node in epigenetic dysregulation giving rise to AML SAN DIEGO , Oct. 28, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical stage biopharmaceutical company focused on the
Toggle Summary Kura Oncology Lead Candidate Tipifarnib Shows Durable Anti-Tumor Activity in HRAS Mutant Head and Neck Cancer in AACR-NCI-EORTC Update
Confirmed partial responses observed in four out of six patients with HRAS mutant HNSCC Tipifarnib demonstrates rapid and durable responses, with partial responses observed beyond one year Registration-enabling study of tipifarnib in HRAS mutant HNSCC planned for 2018 SAN DIEGO , Oct.
Toggle Summary Kura Oncology Announces Late-Breaking Presentations for Tipifarnib in HRAS Mutant Squamous Head and Neck Cancer and for KO-539 in AML at Upcoming AACR-NCI-EORTC International Conference
SAN DIEGO , Oct. 16, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced presentations at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer